Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors

Journal of Clinical Epidemiology

Volumn 80, Issue , 2016, Pages 43-49

  Dunn, Adam G ^a   Zhou, Xujuan ^a,b   Hudgins, Joel ^c   Arachi, Diana ^a   Mandl, Kenneth D ^c,d   Coiera, Enrico ^a   Bourgeois, Florence T ^c,d  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Bibliometrics; Competing interests; Neuraminidase inhibitors; Oseltamivir; Review literature as topic; Zanamivir

Indexed keywords

SIALIDASE INHIBITOR; ENZYME INHIBITOR; SIALIDASE;

ARTICLE; AUTHOR; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FINANCIAL COMPETING INTEREST; FINANCIAL MANAGEMENT; HUMAN; INFLUENZA; PRIORITY JOURNAL; PRODUCTIVITY; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS; LITERATURE; WRITING;

AUTHORSHIP; CONFLICT OF INTEREST; DRUG INDUSTRY; ENZYME INHIBITORS; HUMANS; NEURAMINIDASE; RESEARCH SUPPORT AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84997207737     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2016.07.010     Document Type: Article

References (42)

1. [1] Bastian, H., Glasziou, P., Chalmers, I., Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?. PLoS Med, 7, 2010, e1000326.
2. [2] Fraser, A.G., Dunstan, F.D., On the impossibility of being expert. BMJ, 341, 2010, c6815.
3. [3] Jüni, P., Altman, D.G., Egger, M., Assessing the quality of controlled clinical trials. BMJ 323 (2001), 42–46.
4. [4] Oxman, A.D., Guyatt, G.H., Guidelines for reading literature reviews. CMAJ 138 (1988), 697–703.
5. [5] Mulrow, C.D., The medical review article: state of the science. Ann Intern Med 106 (1987), 485–488.
6. [6] Cipriani, A., Geddes, J., Comparison of systematic and narrative reviews: the example of the atypical antipsychotics. Epidemiol Psichiatr Soc 12 (2003), 146–153.
7. [7] Cook, D.J., Mulrow, C.D., Haynes, R.B., Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 126 (1997), 376–380.
8. [8] Bushman, B.J., Wells, G.L., Narrative impressions of literature: the availability bias and the corrective properties of meta-analytic approaches. Pers Soc Psychol Bull 27 (2001), 1123–1130.
9. [9] Lathyris, D.N., Patsopoulos, N.A., Salanti, G., Ioannidis, J.P., Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest 40 (2010), 172–182.
10. [10] Jagsi, R., Sheets, N., Jankovic, A., Motomura, A.R., Amarnath, S., Ubel, P.A., Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer 115 (2009), 2783–2791.
11. [11] Bekelman, J.E., Li, Y., Gross, C.P., Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289 (2003), 454–465.
12. [12] Davidson, R., Source of funding and outcome of clinical trials. J Gen Intern Med 1 (1986), 155–158.
13. [13] Bes-Rastrollo, M., Schulze, M.B., Ruiz-Canela, M., Martinez-Gonzalez, M.A., Financial conflicts of interest and reporting bias regarding the association between sugar-sweetened beverages and weight gain: a systematic review of systematic reviews. PLoS Med, 10, 2013, e1001578.
14. [14] Dunn, A.G., Arachi, D., Hudgins, J., Tsafnat, G., Coiera, E., Bourgeois, F.T., Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. Ann Intern Med 161 (2014), 513–518.
15. [15] Page, M.J., McKenzie, J.E., Kirkham, J., Dwan, K., Kramer, S., Green, S., et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev, 2014, MR000035.
16. [16] Mendelson, T.B., Meltzer, M., Campbell, E.G., Caplan, A.L., Kirkpatrick, J.N., Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med 171 (2011), 577–584.
17. [17] Norris, S.L., Holmer, H.K., Ogden, L.A., Burda, B.U., Conflict of interest in clinical practice guideline development: a systematic Review. PLoS One, 6, 2011, e25153.
18. [18] Lenzer, J., Why we can't trust clinical guidelines. BMJ, 346, 2013, f3830.
19. [19] Jefferson, T., Jones, M., Doshi, P., Spencer, E.A., Onakpoya, I., Heneghan, C.J., Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ, 348, 2014, g2545.
20. [20] Heneghan, C.J., Onakpoya, I., Thompson, M., Spencer, E.A., Jones, M., Jefferson, T., Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ, 348, 2014, g2547.
21. [21] Cohen, D., Questions remain over safety and effectiveness of oseltamivir. BMJ, 344, 2012, e467.
22. [22] Smith, J.R., Rayner, C.R., Donner, B., Wollenhaupt, M., Klumpp, K., Dutkowski, R., Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv Ther 28 (2011), 927–959.
23. [23] Muthuri, S.G., Venkatesan, S., Myles, P.R., Leonardi-Bee, J., Al Khuwaitir, T.S., Al Mamun, A., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2 (2014), 395–404.
24. [24] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
25. [25] Stelfox, H.T., Chua, G., O'Rourke, K., Detsky, A.S., Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338 (1998), 101–106.
26. [26] Fugh-Berman, A.J., The haunting of medical journals: how ghostwriting sold “HRT”. PLoS Med, 7, 2010, e10800335.
27. [27] Wang, A.T., McCoy, C.P., Murad, M.H., Montori, V.M., Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ, 340, 2010, c1344.
28. [28] Greenberg, S.A., How citation distortions create unfounded authority: analysis of a citation network. BMJ, 339, 2009, b2680.
29. [29] Greenberg, S.A., Understanding belief using citation networks. J Eval Clin Pract 17 (2011), 389–393.
30. [30] Zhou, X., Wang, Y., Tsafnat, G., Coiera, E., Bourgeois, F.T., Dunn, A.G., Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors. J Clin Epidemiol 68 (2015), 87–93.
31. [31] The Editors. Walking the Tightrope of Academia–Industry Relationships. Ann Intern Med 163 (2015), 477–478.
32. [32] Tatsioni, A., Siontis, G.C.M., Ioannidis, J.P., Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med 25 (2010), 914–919.
33. [33] Rasmussen, K., Schroll, J., Gøtzsche, P.C., Lundh, A., Under-reporting of conflicts of interest among trialists: a cross-sectional study. J R Soc Med 108 (2014), 101–107.
34. [34] Bindslev, J.B., Schroll, J., Gøtzsche, P.C., Lundh, A., Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Med Ethics, 14, 2013, 19.
35. [35] Santhakumar, S., Adashi, E.Y., The physician payment sunshine act: testing the value of transparency. JAMA 313 (2015), 23–24.
36. [36] Lichter, A.S., McKinney, R., Toward a harmonized and centralized conflict of interest disclosure: progress from an IOM initiative. JAMA 308 (2012), 2093–2094.
37. [37] Pham-Kanter, G., Act II of the sunshine act. PLoS Med, 11, 2014, e1001754.
38. [38] Loder, E., Brizzell, C., Godlee, F., Revisiting the commercial-academic interface in medical journals. BMJ, 350, 2015, h2957.
39. [39] Barbour, V., Clark, J., Norton, M., Simpson, P., Veitch, E., Does conflict of interest disclosure worsen bias?. PLoS Med, 9, 2012, e1001210.
40. [40] Rosenbaum, L., Beyond moral outrage—weighing the trade-offs of COI regulation. NEJM 372 (2015), 2064–2068.
41. [41] Ioannidis, J.P., Boyack, K.W., Klavans, R., Estimates of the continuously publishing core in the scientific workforce. PLoS One, 9, 2014, e101698.
42. [42] Holleman, F., Uijldert, M., Donswijk, L.F., Gale, E.A., Productivity of authors in the field of diabetes: bibliographic analysis of trial publications. BMJ, 351, 2015, h2638.